Fremanezumab: Difference between revisions
Content deleted Content added
No edit summary |
WildCation (talk | contribs) Chembox edits: Set CSID to none |
||
| Line 42: | Line 42: | ||
| UNII = PF8K38CG54 |
| UNII = PF8K38CG54 |
||
| synonyms = TEV-48125 |
| synonyms = TEV-48125 |
||
| ChemSpiderID = none |
|||
}} |
}} |
||
'''Fremanezumab''' ([[International Nonproprietary Name|INN]]) is a humanized [[monoclonal antibody]] directed against [[Calcitonin gene-related peptide|calcitonin-related polypeptides]] alpha and beta.<ref>{{cite journal|title=International Nonproprietary Names for Pharmaceutical Substances (INN) |journal=WHO Drug Information |volume=31|issue=1|year=2017|publisher=WHO |url=http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf?ua=1}}</ref> It is being developed for the prevention of [[migraine]] (and [[cluster headache]]) by [[Teva Pharmaceutical Industries|Teva]]. |
'''Fremanezumab''' ([[International Nonproprietary Name|INN]]) is a humanized [[monoclonal antibody]] directed against [[Calcitonin gene-related peptide|calcitonin-related polypeptides]] alpha and beta.<ref>{{cite journal|title=International Nonproprietary Names for Pharmaceutical Substances (INN) |journal=WHO Drug Information |volume=31|issue=1|year=2017|publisher=WHO |url=http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf?ua=1}}</ref> It is being developed for the prevention of [[migraine]] (and [[cluster headache]]) by [[Teva Pharmaceutical Industries|Teva]]. |
||
Revision as of 12:44, 17 April 2018
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CALCA, CALCB |
| Clinical data | |
| Other names | TEV-48125 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Fremanezumab (INN) is a humanized monoclonal antibody directed against calcitonin-related polypeptides alpha and beta.[1] It is being developed for the prevention of migraine (and cluster headache) by Teva.
It is in Phase III clinical trials as of July 2017[update].[2][3][4] Results of two pivotal phase 3 studies were presented in 2017.[5] Teva hopes for US FDA approval in 2018.[5]
See also
- Other anti-migraine antibodies blocking the CGRP pathway
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 31 (1). WHO. 2017.
- ^ H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
- ^ A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)
- ^ A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
- ^ a b Fremanezumab for Migraine Shows Impressive Results Nov 2017
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |